Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H5I2NO3 |
| Molecular Weight | 404.9284 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CN1C=C(I)C(=O)C(I)=C1
InChI
InChIKey=PVBALTLWZVEAIO-UHFFFAOYSA-N
InChI=1S/C7H5I2NO3/c8-4-1-10(3-6(11)12)2-5(9)7(4)13/h1-2H,3H2,(H,11,12)
| Molecular Formula | C7H5I2NO3 |
| Molecular Weight | 404.9284 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Iodopyracet (Diodone) is a radiocontrast agent used in urography before 1950. Renal clearance of iodopyracet is characterized by supply-limited elimination at low plasma concentrations and capacity-limited elimination at high plasma levels. Iodopyracet to be an effective agent for the estimation of renal plasma flow and tubular function has been used extensively in physiological studies. In 1945 was found, that p-aminohippuric acid was in some ways superior to diodone for these estimations in man because the urine and plasma blanks are small and because diodone penetrates human red blood cells whereas p-aminohippuric acid does not.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1777665 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14734677 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
10 g single, intravenous Dose: 10 g Route: intravenous Route: single Dose: 10 g Sources: |
unhealthy |
Other AEs: Nausea and vomiting, Urticaria... Other AEs: Nausea and vomiting (severe, 2 patients) Sources: Urticaria (8 patients) Sleepiness (34 patients) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Sleepiness | 34 patients | 10 g single, intravenous Dose: 10 g Route: intravenous Route: single Dose: 10 g Sources: |
unhealthy |
| Urticaria | 8 patients | 10 g single, intravenous Dose: 10 g Route: intravenous Route: single Dose: 10 g Sources: |
unhealthy |
| Nausea and vomiting | severe, 2 patients | 10 g single, intravenous Dose: 10 g Route: intravenous Route: single Dose: 10 g Sources: |
unhealthy |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2706315
3.0 g, administered i.v.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:00:13 GMT 2025
by
admin
on
Mon Mar 31 21:00:13 GMT 2025
|
| Record UNII |
NLX9TZ649P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
202-932-5
Created by
admin on Mon Mar 31 21:00:13 GMT 2025 , Edited by admin on Mon Mar 31 21:00:13 GMT 2025
|
PRIMARY | |||
|
141062
Created by
admin on Mon Mar 31 21:00:13 GMT 2025 , Edited by admin on Mon Mar 31 21:00:13 GMT 2025
|
PRIMARY | |||
|
NLX9TZ649P
Created by
admin on Mon Mar 31 21:00:13 GMT 2025 , Edited by admin on Mon Mar 31 21:00:13 GMT 2025
|
PRIMARY | |||
|
101-29-1
Created by
admin on Mon Mar 31 21:00:13 GMT 2025 , Edited by admin on Mon Mar 31 21:00:13 GMT 2025
|
PRIMARY | |||
|
9304
Created by
admin on Mon Mar 31 21:00:13 GMT 2025 , Edited by admin on Mon Mar 31 21:00:13 GMT 2025
|
PRIMARY | |||
|
DTXSID7043794
Created by
admin on Mon Mar 31 21:00:13 GMT 2025 , Edited by admin on Mon Mar 31 21:00:13 GMT 2025
|
PRIMARY | |||
|
60718
Created by
admin on Mon Mar 31 21:00:13 GMT 2025 , Edited by admin on Mon Mar 31 21:00:13 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |